San Diego-dependent Viking Therapeutics marked itself as a serious competitor while in the weight loss drug market in February immediately after revealing promising data from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection and in March the comp